These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 37446038)

  • 21. Pathophysiology of dry eye disease and novel therapeutic targets.
    Messmer EM
    Exp Eye Res; 2022 Apr; 217():108944. PubMed ID: 35077753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A distinct cytokines profile in tear film of dry eye disease (DED) patients with HIV infection.
    Agrawal R; Balne PK; Veerappan A; Au VB; Lee B; Loo E; Ghosh A; Tong L; Teoh SC; Connolly J; Tan P
    Cytokine; 2016 Dec; 88():77-84. PubMed ID: 27585367
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ion channels in dry eye disease.
    Ashok N; Khamar P; D'Souza S; Gijs M; Ghosh A; Sethu S; Shetty R
    Indian J Ophthalmol; 2023 Apr; 71(4):1215-1226. PubMed ID: 37026252
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NLRP3 inflammasome in ischemic stroke: As possible therapeutic target.
    Alishahi M; Farzaneh M; Ghaedrahmati F; Nejabatdoust A; Sarkaki A; Khoshnam SE
    Int J Stroke; 2019 Aug; 14(6):574-591. PubMed ID: 30940045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. sPLA
    Wei Y; Asbell PA
    Exp Eye Res; 2020 Dec; 201():108209. PubMed ID: 33011237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Capsanthin from Capsicum annum fruits exerts anti-glaucoma, antioxidant, anti-inflammatory activity, and corneal pro-inflammatory cytokine gene expression in a benzalkonium chloride-induced rat dry eye model.
    Shanmugham V; Subban R
    J Food Biochem; 2022 Oct; 46(10):e14352. PubMed ID: 35892258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical impact of inflammation in dry eye disease: proceedings of the ODISSEY group meeting.
    Baudouin C; Irkeç M; Messmer EM; Benítez-Del-Castillo JM; Bonini S; Figueiredo FC; Geerling G; Labetoulle M; Lemp M; Rolando M; Van Setten G; Aragona P;
    Acta Ophthalmol; 2018 Mar; 96(2):111-119. PubMed ID: 28390092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The inflammasome pathway: A key player in ocular surface and anterior segment diseases.
    Mandell JT; de Rivero Vaccari JP; Sabater AL; Galor A
    Surv Ophthalmol; 2023; 68(2):280-289. PubMed ID: 35798189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DRY EYE DISEASE. A REVIEW.
    Zemanová M
    Cesk Slov Oftalmol; 2021; 77(3):107–119. PubMed ID: 34107689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [If Artificial Tears Aren't Enough. The Importance of Inflammatory Processes in Dry Eye Disease. Practical Aspects of an Anti-Inflammatory Therapy of Dry Eye Disease].
    Pleyer U; Geerling G; Schrader S; Jacobi C; Kimmich F; Messmer E
    Klin Monbl Augenheilkd; 2020 May; 237(5):655-668. PubMed ID: 32434249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of small molecule inhibitors targeting NLRP3 inflammasome pathway for inflammatory diseases.
    Zhang X; Xu A; Lv J; Zhang Q; Ran Y; Wei C; Wu J
    Eur J Med Chem; 2020 Jan; 185():111822. PubMed ID: 31699536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Defining Dry Eye from a Clinical Perspective.
    Tsubota K; Pflugfelder SC; Liu Z; Baudouin C; Kim HM; Messmer EM; Kruse F; Liang L; Carreno-Galeano JT; Rolando M; Yokoi N; Kinoshita S; Dana R
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The NLRP3 Inflammasome as a Pharmacological Target.
    Marchetti C
    J Cardiovasc Pharmacol; 2019 Oct; 74(4):285-296. PubMed ID: 31335445
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting NLRP3 inflammasome as a promising approach for treatment of diabetic nephropathy: Preclinical evidences with therapeutic approaches.
    Ram C; Jha AK; Ghosh A; Gairola S; Syed AM; Murty US; Naidu VGM; Sahu BD
    Eur J Pharmacol; 2020 Oct; 885():173503. PubMed ID: 32858047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A new approach for better comprehension of diseases of the ocular surface].
    Baudouin C
    J Fr Ophtalmol; 2007 Mar; 30(3):239-46. PubMed ID: 17417148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reconsidering the central role of mucins in dry eye and ocular surface diseases.
    Baudouin C; Rolando M; Benitez Del Castillo JM; Messmer EM; Figueiredo FC; Irkec M; Van Setten G; Labetoulle M
    Prog Retin Eye Res; 2019 Jul; 71():68-87. PubMed ID: 30471351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Specific NLRP3 inflammasome inhibitors: promising therapeutic agents for inflammatory diseases.
    Vong CT; Tseng HHL; Yao P; Yu H; Wang S; Zhong Z; Wang Y
    Drug Discov Today; 2021 Jun; 26(6):1394-1408. PubMed ID: 33636340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent advances in drug treatments for dry eye disease.
    Coco G; Ambrosini G; Poletti S; Meliante LA; Taloni A; Scorcia V; Giannaccare G
    Expert Opin Pharmacother; 2023; 24(18):2059-2079. PubMed ID: 37804227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tear Proteomics Approach to Monitoring Sjögren Syndrome or Dry Eye Disease.
    Kuo MT; Fang PC; Chao TL; Chen A; Lai YH; Huang YT; Tseng CY
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31010136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting.
    Baudouin C; Aragona P; Messmer EM; Tomlinson A; Calonge M; Boboridis KG; Akova YA; Geerling G; Labetoulle M; Rolando M
    Ocul Surf; 2013 Oct; 11(4):246-58. PubMed ID: 24112228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.